160 related articles for article (PubMed ID: 36042365)
1. Clinical parameter-based prediction of DNA methylation classification generates a prediction model of prognosis in patients with juvenile myelomonocytic leukemia.
Imaizumi T; Meyer J; Wakamatsu M; Kitazawa H; Murakami N; Okuno Y; Yoshida T; Sajiki D; Hama A; Kojima S; Takahashi Y; Loh M; Stieglitz E; Muramatsu H
Sci Rep; 2022 Aug; 12(1):14753. PubMed ID: 36042365
[TBL] [Abstract][Full Text] [Related]
2. Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia.
Kitazawa H; Okuno Y; Muramatsu H; Aoki K; Murakami N; Wakamatsu M; Suzuki K; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Kawashima N; Nishikawa E; Narita A; Nishio N; Hama A; Loh ML; Stieglitz E; Kojima S; Takahashi Y
Blood Adv; 2021 Dec; 5(24):5507-5518. PubMed ID: 34580726
[TBL] [Abstract][Full Text] [Related]
3. International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
Schönung M; Meyer J; Nöllke P; Olshen AB; Hartmann M; Murakami N; Wakamatsu M; Okuno Y; Plass C; Loh ML; Niemeyer CM; Muramatsu H; Flotho C; Stieglitz E; Lipka DB
Clin Cancer Res; 2021 Jan; 27(1):158-168. PubMed ID: 33139265
[TBL] [Abstract][Full Text] [Related]
4. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
5. Gene mutations do not operate in a vacuum: the increasing importance of epigenetics in juvenile myelomonocytic leukemia.
Flotho C
Epigenetics; 2019 Mar; 14(3):236-244. PubMed ID: 30773984
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
Stieglitz E; Mazor T; Olshen AB; Geng H; Gelston LC; Akutagawa J; Lipka DB; Plass C; Flotho C; Chehab FF; Braun BS; Costello JF; Loh ML
Nat Commun; 2017 Dec; 8(1):2127. PubMed ID: 29259179
[TBL] [Abstract][Full Text] [Related]
7. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
Fluhr S; Boerries M; Busch H; Symeonidi A; Witte T; Lipka DB; Mücke O; Nöllke P; Krombholz CF; Niemeyer CM; Plass C; Flotho C
Clin Epigenetics; 2016; 8():50. PubMed ID: 27158276
[TBL] [Abstract][Full Text] [Related]
8. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
9. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
10. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
11. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
12. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.
Wilhelm T; Lipka DB; Witte T; Wierzbinska JA; Fluhr S; Helf M; Mücke O; Claus R; Konermann C; Nöllke P; Niemeyer CM; Flotho C; Plass C
Epigenetics; 2016; 11(2):110-9. PubMed ID: 26891149
[TBL] [Abstract][Full Text] [Related]
14. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
[TBL] [Abstract][Full Text] [Related]
15. RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.
Poetsch AR; Lipka DB; Witte T; Claus R; Nöllke P; Zucknick M; Olk-Batz C; Fluhr S; Dworzak M; De Moerloose B; Starý J; Zecca M; Hasle H; Schmugge M; van den Heuvel-Eibrink MM; Locatelli F; Niemeyer CM; Flotho C; Plass C
Epigenetics; 2014 Sep; 9(9):1252-60. PubMed ID: 25147919
[TBL] [Abstract][Full Text] [Related]
16. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
[TBL] [Abstract][Full Text] [Related]
17. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.
Olk-Batz C; Poetsch AR; Nöllke P; Claus R; Zucknick M; Sandrock I; Witte T; Strahm B; Hasle H; Zecca M; Stary J; Bergstraesser E; De Moerloose B; Trebo M; van den Heuvel-Eibrink MM; Wojcik D; Locatelli F; Plass C; Niemeyer CM; Flotho C;
Blood; 2011 May; 117(18):4871-80. PubMed ID: 21406719
[TBL] [Abstract][Full Text] [Related]
18. Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia.
Fiñana C; Gómez-Molina N; Alonso-Moreno S; Belver L
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267643
[TBL] [Abstract][Full Text] [Related]
19. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP
Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299
[TBL] [Abstract][Full Text] [Related]
20. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
